secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2022-03-25T23:59:59+00:00
Accession:  0000950170-22-004612
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma appoints Michael L. Derby to Board of Directors
-------------------------------------------------------------

- Appointed effective March 24, 2022; term expires at 2022 annual meeting.
- Receives standard non-employee director compensation: $30,000 annual cash plus equity awards.
- Appointment fulfills undertaking from Grace Therapeutics acquisition (Aug 2021) to designate a Grace stockholder representative.
- Derby has over 20 years biopharma experience; founded/co-founded seven companies including TardiMed Sciences.
- Board determined Derby is independent under SEC and Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017022004612/0000950170-22-004612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017022004612/acst-20220324.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer